REVIEW ARTICLE
Year : 2013 | Volume
: 6 | Issue : 2 | Page : 93--98
Current evidence supporting «DQ»letrozole«DQ» for ovulation induction
Sujata Kar
Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha, India
Correspondence Address:
Sujata Kar
Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha - 751 001
India
Aromatase inhibitor «DQ»letrozole«DQ» was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Letrozole appears to be a good option, with its oral route of administration, cost, shorter half-life and negligible side effects. However, the verdict on efficacy and safety of letrozole is still uncertain. This review explores the current scientific data supporting letrozole for OI.
How to cite this article:
Kar S. Current evidence supporting "letrozole" for ovulation induction.J Hum Reprod Sci 2013;6:93-98
|
How to cite this URL:
Kar S. Current evidence supporting "letrozole" for ovulation induction. J Hum Reprod Sci [serial online] 2013 [cited 2023 Mar 29 ];6:93-98
Available from: https://www.jhrsonline.org/article.asp?issn=0974-1208;year=2013;volume=6;issue=2;spage=93;epage=98;aulast=Kar;type=0 |
|
